[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold company common stock in two reported transactions under a 10b5-1 plan and to cover tax withholding on vested performance-based restricted stock units. On 08/19/2025 he sold 1,750 shares at a weighted average price of $16.1604, leaving him with 107,249 shares beneficially owned. On 08/21/2025 he sold 2,438 shares at a weighted average price of $15.5738, leaving him with 104,811 shares beneficially owned.

The filing notes the 08/21 trades were effected pursuant to a 10b5-1 trading plan adopted December 12, 2024 (plan end date February 27, 2026). The 08/19 sale was to cover tax withholding on vested performance-based RSUs. Sales occurred in multiple transactions at noted price ranges and the reporting person offers to provide detailed per-trade allocations on request.

Positive

• Disclosures comply with Section 16 reporting and identify the 10b5-1 trading plan adoption date and end date
• Sale for tax withholding on vested performance-based RSUs was explicitly disclosed, clarifying the reason for part of the disposition
• Reporting person offers to provide per-trade allocation details on request, improving transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sales: tax-withholding disposition and 10b5-1 plan trades; no additional material disclosures.

The Form 4 documents two non-derivative dispositions by a senior executive totaling 4,188 shares across 08/19/2025 and 08/21/2025. The 08/19 sales were explicitly to satisfy tax withholding obligations tied to the vesting of performance-based restricted stock units; the 08/21 sales were executed under a pre-established 10b5-1 plan. Prices are presented as weighted averages with disclosed ranges. From an investor-significance perspective, the filing shows compliance with tax and trading-plan procedures and does not disclose any other corporate or financial developments.

Corporate Governance Expert

TL;DR: Controlled, rule-compliant insider activity consistent with compensation mechanics and a trading plan.

The reporting clarifies the governance context: the sales include a tax-withholding sale following RSU vesting and transactions pursuant to a 10b5-1 plan adopted 12/12/2024 (plan end 02/27/2026). The filer affirms willingness to provide transaction-level allocation within provided price ranges. This transparency aligns with best practices for insider disclosure; no amendments or other governance actions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S(1)		1,750(1)	D	$16.1604(2)	107,249	D
Common Stock	08/21/2025		S(3)		2,438(3)	D	$15.5738(4)	104,811	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.87 to $16.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

4. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.43 to $15.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's Title: Executive Vice President and Chief Medical Officer

	/s/ Latha Vairavan, Attorney-in-Fact for Patrick Burnett	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Patrick Burnett sell according to the ARQT Form 4?

He sold 1,750 shares on 08/19/2025 and 2,438 shares on 08/21/2025, totaling 4,188 shares.

Why were some shares sold by the Arcutis (ARQT) executive on 08/19/2025?

The filing states the 08/19 sale was to cover tax withholding obligations arising from the vesting of performance-based restricted stock units.

Were the 08/21/2025 sales for ARQT part of a trading plan?

Yes. The transactions on 08/21/2025 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 with a plan end date of February 27, 2026.

What prices were reported for the ARQT share sales?

The Form 4 reports weighted average prices: $16.1604 for the 08/19 sales (range $15.87–$16.73) and $15.5738 for the 08/21 sales (range $15.43–$15.65).

How many ARQT shares did Burnett beneficially own after each transaction?

After the 08/19/2025 sale he beneficially owned 107,249 shares; after the 08/21/2025 sale he beneficially owned 104,811 shares.